A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Bladder Cancer Information Center
Folder Conference Coverage

A report from the 2008 ASCO Genitourinary Cancers Symposium - CME

ASCO 2007: Update on the Management of Genitourinary Malignancies

 
People Current Topics

Gemzar®-Based Regimens for the Treatment of Locally Advanced or Metastatic Bladder Cancer

 
News Latest Bladder Cancer News

The Incidence of Smoking-related Bladder Cancer May Be Increasing (11/19/2009)
Researchers from the National Cancer Institute and Dartmouth Medical School have reported that the risk of developing smoking-related bladder cancer has increased in New Hampshire over the risk observed in the 1990s. The details of this study appeared in the November 18, 2009 issue of the Journal of the National Cancer Institute.

Intravesical Taxotere® Maintenance Therapy May Improve Treatment of Superficial Bladder Cancer Refractory to BCG (11/18/2009)
Researchers from Columbia University have reported that induction and maintenance therapy with intravesical Taxotere® (docetaxel) is well tolerated and effective for treatment of patients with non-muscle-invasive bladder cancer who are refractory to Bacilli Calmette-Guerin (BCG) therapy. The details of this study were reported in the October 2009 issue of British Journal of Urology International.

Carbogen and Nicotinamide Improves Survival of Patients with Advanced Bladder Cancer Receiving Radiotherapy (11/11/2009)
Researchers from the UK have reported that patients with locally advanced bladder cancer treated with concomitant carbogen, nicotinamide, and radical accelerated radiotherapy have a 13% improved three-year survival compared with patients treated with radiotherapy alone. The details of this Phase III randomized trial were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.

Gemzar® More Effective than Mutamycin® for Recurrent Superficial Bladder Cancer (10/23/2009)
Researchers from Italy have reported that intrabladder treatment with Gemzar® (gemcitabine) is more effective than Mutamycin® (mitomycin C) for the treatment of recurrent bladder cancer. The details of this randomized trial were published early online in the Journal of Clinical Oncology on October 19.

Multimodality Therapy with Hyperthermia Promising for High-risk Bladder Cancer (10/22/2009)
Researchers from Germany have reported that a strategy of transurethral resection followed by chemoradiotherapy with regional deep hyperthermia results in local recurrence-free survival of 85% in patients with high-risk Stage I and II bladder cancer. The details of this study were published early online in Radiotherapy and Oncology on October 19, 2009.

More Bladder Cancer News »

Bladder Cancer Drug Pipeline

What's in the pipeline for Bladder Cancer.
Newsletters

Register in our member center today to receive a monthly newsletter with clinical news, conference coverage, and current topic updates.
 
Information by Cancer Type

 Supportive Care Centers

 Physician Resources




© 1998-2007 CancerConsultants.com  All Rights Reserved.